265 related articles for article (PubMed ID: 3023426)
1. Peptide histidine-methionine immunoreactivity in plasma and tissue from patients with vasoactive intestinal peptide-secreting tumors and watery diarrhea syndrome.
Yiangou Y; Williams SJ; Bishop AE; Polak JM; Bloom SR
J Clin Endocrinol Metab; 1987 Jan; 64(1):131-9. PubMed ID: 3023426
[TBL] [Abstract][Full Text] [Related]
2. Cosecretion of peptide histidine methionine (PHM) and vasoactive intestinal peptide (VIP) in patients with VIP-producing tumors.
Fahrenkrug J; Pedersen JH
Peptides; 1986; 7(5):717-21. PubMed ID: 3797338
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a pancreatic tumor containing vasoactive intestinal peptide, neurotensin, and pancreatic polypeptide.
Shulkes A; Boden R; Cook I; Gallagher N; Furness JB
J Clin Endocrinol Metab; 1984 Jan; 58(1):41-8. PubMed ID: 6315763
[TBL] [Abstract][Full Text] [Related]
4. Diarrhoea in vipoma patients associated with cosecretion of a second active peptide (peptide histidine isoleucine) explained by single coding gene.
Bloom SR; Christofides ND; Delamarter J; Buell G; Kawashima E; Polak JM
Lancet; 1983 Nov; 2(8360):1163-5. PubMed ID: 6139527
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide (VIP) secreting tumour of the pancreas.
Sandström R; Alhava EM; Poikolainen E; Puittinen J; Soimakallio S
Ann Chir Gynaecol; 1981; 70(3):124-7. PubMed ID: 6275768
[TBL] [Abstract][Full Text] [Related]
6. Molecular forms of peptide histidine isoleucine-like immunoreactivity in the gastrointestinal tract. Nonequimolar levels of peptide histidine isoleucine and vasoactive intestinal peptide in the stomach explained by the presence of a big peptide histidine isoleucine-like molecule.
Yiangou Y; Christofides ND; Blank MA; Yanaihara N; Tatemoto K; Bishop AE; Polak JM; Bloom SR
Gastroenterology; 1985 Sep; 89(3):516-24. PubMed ID: 3839480
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) in human eccrine sweat glands: demonstration of innervation, specific binding sites and presence in secretions.
Eedy DJ; Shaw C; Armstrong EP; Johnston CF; Buchanan KD
Br J Dermatol; 1990 Jul; 123(1):65-76. PubMed ID: 2390496
[TBL] [Abstract][Full Text] [Related]
8. Distribution, plasma concentration, and in vivo prolactin-releasing activity of peptide histidine methionine in humans.
Sasaki A; Sato S; Go MG; Shimizu Y; Murakami O; Hanew K; Yumita S; Andoh N; Sasano N; Yoshinaga K
J Clin Endocrinol Metab; 1987 Oct; 65(4):683-8. PubMed ID: 3654914
[TBL] [Abstract][Full Text] [Related]
9. Molecular forms of glucagon-like peptide-1 in human pancreas and glucagonomas.
Uttenthal LO; Ghiglione M; George SK; Bishop AE; Polak JM; Bloom SR
J Clin Endocrinol Metab; 1985 Sep; 61(3):472-9. PubMed ID: 2991321
[TBL] [Abstract][Full Text] [Related]
10. PreproVIP-derived peptides in tissue and plasma from patients with VIP-producing tumours.
Rønnov-Jensen D; Gether U; Fahrenkrug J
Eur J Clin Invest; 1991 Apr; 21(2):154-60. PubMed ID: 1647952
[TBL] [Abstract][Full Text] [Related]
11. Peptide histidine methionine and vasoactive intestinal peptide levels in human cerebrospinal fluid: age-related changes and absence of a correlation with serum prolactin.
Yasuda M; Minamitani N; Maeda K; Chihara K; Fujita K; Kobayashi I
Regul Pept; 1993 Jul; 46(3):565-73. PubMed ID: 8210516
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic endocrine tumours associated with WDHA syndrome. An immunohistochemical and electron microscopic study.
Ooi A; Kameya T; Tsumuraya M; Yamaguchi K; Abe K; Shimosato Y; Yanaihara N
Virchows Arch A Pathol Anat Histopathol; 1985; 405(3):311-23. PubMed ID: 2579503
[TBL] [Abstract][Full Text] [Related]
13. [Vasoactive intestinal peptide (VIP) in the Verner-Morrison syndrome (author's transl)].
Grenier JF; Marescaux J; Michel F; Sava G; Kachelhoffer J
Nouv Presse Med; 1979 Apr; 8(18):1505-8. PubMed ID: 224378
[TBL] [Abstract][Full Text] [Related]
14. Evidence for common precursors but differential processing of VIP and PHM in VIP-producing tumors.
Fahrenkrug J
Peptides; 1985; 6(3):357-61. PubMed ID: 3840886
[TBL] [Abstract][Full Text] [Related]
15. Peptide histidine methionine may be a prolactin-releasing hormone in humans.
Sasaki A; Sato S; Shinkawa O; Go M; Otsuka T; Sugawara A; Shimizu Y; Murakami O; Hanew K; Andoh N
J Clin Endocrinol Metab; 1988 Jun; 66(6):1202-7. PubMed ID: 3131380
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic vasoactive intestinal polypeptide-secreting tumor: report of a case.
Sheu HW; Chou SY; Yang KC; Kao CR; Yang TL; Shih CC
Taiwan Yi Xue Hui Za Zhi; 1989 Sep; 88(9):931-5. PubMed ID: 2559939
[TBL] [Abstract][Full Text] [Related]
17. Concentrations and distribution of vasoactive intestinal peptide (VIP), peptide histidine isoleucine (PHI) and peptide histidine valine (PHV) in the cerebral cortex and the suprachiasmatic nucleus of the mouse.
Mikkelsen JD; Fahrenkrug J
Brain Res; 1994 Sep; 656(1):95-107. PubMed ID: 7804850
[TBL] [Abstract][Full Text] [Related]
18. Peptide histidine methionine and vasoactive intestinal peptide: occurrence and relaxant effect in the human female reproductive tract.
Palle C; Ottesen B; Jørgensen J; Fahrenkrug J
Biol Reprod; 1989 Dec; 41(6):1103-11. PubMed ID: 2624870
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of vasoactive intestinal peptide and neurotensin secretion by pentagastrin in a patient with VIPoma syndrome.
Brunt LM; Mazoujian G; O'Dorisio TM; Wells SA
Surgery; 1994 Mar; 115(3):362-9. PubMed ID: 8128360
[TBL] [Abstract][Full Text] [Related]
20. Stimulation by peptide histidine methionine (PHM) of adrenocorticotropin secretion in patients with Cushing's disease: a comparison with the effect of vasoactive intestinal peptide (VIP) and a study on the effect of combined administration of corticotropin-releasing hormone with PHM or VIP.
Watanobe H; Tamura T
J Clin Endocrinol Metab; 1994 Jun; 78(6):1372-7. PubMed ID: 8200939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
